Insider buying last 90 days
No open-market insider purchases were filed for IRMD in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every IRMD insider filing, plotted on the chart in Gekko.Open IRMD in Gekko
NASDAQ: IRMD
iRadimed (IRMD) Stock Analysis & Forecast
Oct 12 close
$89.47+2.02 (+2.3%)
Gekko Brief
AI summaryOct 12 closeIRadimed closed at $89.47, up 2.3%, with price sitting between its 50-day average of $86.49 and 200-day average of $93.37, a mixed trend signal. The stock sits in the GekkoIndex Neutral zone with a reading of 50.8, down 6.7 over the past five sessions. Price trades 9.1% above Gekko Fair Value of $82.01, a gap that bears watching.
Over the last month the stock has gained 8.8%, though it remains down 2.4% over three months and 4.4% over six months, with a 52-week range spanning $71.34 to $107.90. Two analysts cover the name, one with a buy rating and one with a hold, with a consensus price target of $118 implying 31.9% upside from current levels. No insider, Congress, or unusual options activity appears in the recent windows, and no billionaire holders are recorded, leaving smart-money positioning quiet for now.
Earnings are due on 2 November 2026, 20 days out, which falls within a typical 20-trading-day holding window and follows a July quarter where EPS of $0.41 missed the $0.42 estimate, triggering a 3.8% reaction. The company has beaten estimates in 5 of its last 8 quarters, with an average absolute post-earnings move of 8.6%. Seasonally, the next 20 trading days have historically averaged a 9.5% gain over five years, rising in 5 of those years, a pattern worth noting alongside the upcoming report.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
iRadimed price vs fair value
Close $89.47200-day averageGekko Fair Value $82.01
iRadimed quick facts
- Market cap
- $1.14B
- P/E ratio
- 48
- Forward P/E
- 41.2
- EPS, TTM
- $1.79
- Revenue, TTM
- $86.34M
- Profit margin
- 26.7%
- Dividend yield
- 0.90%
- Beta
- 0.91
- Volume
- 111,498 avg 120,610
- 1-year return
- +18.6%
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±6%
- 50-day average
- $86.49
- 200-day average
- $93.37
- Next earnings
- Nov 2
- Shares outstanding
- 12.79M
iRadimed swing-trade checklist
iRadimed scores 1 supportive, 2 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive2 mixed2 headwinds
- Trendmixed
Averages disagree
Close $89.47 sits between the 50-day ($86.49) and 200-day ($93.37) averages, or the averages disagree.
See the chart - GekkoIndexmixed
50.8, Neutral
Reading 50.8 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
9.1% above
Price is 9.1% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 21 days
Reports on Nov 2, 2026, 21 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+9.5% on average
From this point in the calendar, the next 20 trading days averaged +9.5% over 5 years, rising in 5 of them.
See seasonality
A description of current data, not a recommendation. How this page works
iRadimed stock chart and price history
iRadimed closed at $89.47 on Oct 12, 2026, +18.6% over the past year, inside a 52-week range of $71.34 to $107.90.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +8.8%
- 3 months
- −2.4%
- 6 months
- −4.4%
- 1 year
- +18.6%
The full IRMD chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IRMD in Gekko
Follow iRadimed through every session
Put IRMD on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track IRMD in GekkoFree for 7 days. No credit card required.
iRadimed GekkoIndex: the smart money zone
iRadimed’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.8, in the Neutral zone, down 6.7 points over five sessions.
50.8Neutral
Down 6.7 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 13 | +4.1% | +2.6% | ||
| Accumulation | 171 | +0.5% | +1.8% | ||
| Neutral (current zone) | 471 | +0.5% | +2.4% | ||
| Distribution | 23 | −0.8% | +0.9% | ||
| Selling | 4 | Too few readings yet | |||
Average IRMD share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the IRMD price, zone by zone.Track IRMD in Gekko
Is iRadimed stock overvalued? Gekko Fair Value
iRadimed trades 9.1% above Gekko Fair Value of $82.01, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what iRadimed shares are worth, recalculated every trading day.
$82.01
Gekko Fair Value, Oct 10, 2026
9.1% Overvalued
At the end of Aug 2026 the price was 1.3% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open IRMD in Gekko
iRadimed insider and Congress trading
No open-market insider purchases were filed for iRadimed, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in IRMD were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for IRMD, plotted on the chart in Gekko.Open IRMD in Gekko
Buybacks
iRadimed has been buying back its own shares.
- Bought back, year ended Dec 31, 2018
- $310K
- As a share of market cap
- 0.03%
From company filings.
Hedge funds and billionaires quarter ended Mar 31
0of the funds Gekko tracks hold IRMD.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
iRadimed earnings: next date and track record
iRadimed reports on Nov 2, 2026 (21 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 2, 2026
21 days away
- EPS estimate
- $0.55
- Revenue estimate
- $23.47M
5 of 8reports beat the EPS estimate
±8.6%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 31, 2026 AI summary
- What they said
- IRadimed achieved Q2 2026 revenue of $20.5M with GAAP EPS of $0.41 and non-GAAP EPS of $0.46, meeting guidance. The company successfully produced 130-135 units of its new 3870 MR IV pump in its first general release quarter. Bookings exceeded shipments by more than double, with 70% of replacements upgrading to 4-channel quad systems at ASPs above $110,000. Patient monitors hit a domestic record of 71 units.
- Guidance
- Q3 production targets over 300 3870 pump units, more than doubling Q2 output. Management expects Q2 startup costs to be reduced by more than 50% in Q3 with improving earnings. Q4 targets near historic manufacturing efficiencies with return to strong historical growth rates.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 31, 2026 | $0.41 est $0.42 | $20.47M est $20.35M | −3.8% |
| May 1, 2026 | $0.49 est $0.45 | $21.98M est $21.32M | +1.8% |
| Feb 10, 2026 | $0.54 est $0.48 | $22.69M est $21.60M | +7.4% |
| Nov 3, 2025 | $0.47 est $0.46 | $21.20M est $21.60M | +12.9% |
| Aug 1, 2025 | $0.49 est $0.45 | $20.41M est $20.50M | +21.2% |
| May 5, 2025 | $0.42 est $0.43 | $19.51M est $19.33M | −4.6% |
| Feb 13, 2025 | $0.40 est $0.41 | $19.39M est $19.20M | −8.7% |
| Oct 31, 2024 | $0.43 est $0.39 | $18.33M est $18.94M | −8.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
iRadimed stock forecast and analyst price targets
Analysts’ average 12-month price target for iRadimed is $118.00, +31.9% from the last close, from 2 firms rating the stock in the last 90 days.
$118.00consensus 12-month target, +31.9% from the last close
Each firm’s latest rating in the last 90 days: 2 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 22 | Needham | — | — |
| Aug 3 | Lake Street | $120 | +34.1% |
+2.4%average 20-day move after past Neutral readings
+9.5%average move over the next 20 trading days in the last 5 years
±2.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
iRadimed seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, iRadimed averaged +9.5% across the last 5 years, rising in 5 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.2% | 4 of 5 |
| Next 10 trading days | +3.5% | 4 of 5 |
| Next 15 trading days | +5.9% | 5 of 5 |
| Next 20 trading days | +9.5% | 5 of 5 |
| Next 30 trading days | +11.5% | 5 of 5 |
For scale, IRMD’s typical 20-trading-day move in either direction is about 6%.
iRadimed market cap and key statistics
iRadimed’s market cap is $1.14B, with a P/E ratio of 48 and revenue of $86.34M over the last twelve months.
Valuation
- Market cap
- $1.14B
- P/E ratio
- 48
- Forward P/E
- 41.2
- EPS, TTM
- $1.79
- Gekko Fair Value
- $82.01
Trading
- Volume
- 111,498
- Avg volume, 20 days
- 120,610
- 52-week high
- $107.90
- 52-week low
- $71.34
- Shares outstanding
- 12.79M
Financials
- Revenue, TTM
- $86.34M
- Profit margin
- 26.7%
- Return on equity
- 23.5%
- Quarterly earnings growth, YoY
- −9.3%
Risk and income
- Beta
- 0.91
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±6%
- Dividend yield
- 0.90%
iRadimed peers
iRadimed’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
iRadimed stock FAQ
What is iRadimed’s market cap?
iRadimed’s market cap is $1.14B at the Oct 12, 2026 close of $89.47, with 12.79M shares outstanding. The shares trade on a P/E ratio of 48.
What is the iRadimed stock forecast?
The consensus analyst 12-month price target for iRadimed is $118.00, +31.9% from the last close. Of the 2 firms that rated the stock in the last 90 days, 1 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is iRadimed stock overvalued or undervalued?
On Gekko’s estimate iRadimed is overvalued: the Oct 12, 2026 close of $89.47 is 9.1% above Gekko Fair Value of $82.01. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does iRadimed report earnings next?
iRadimed is expected to report on Nov 2, 2026 (21 days away). Analysts expect earnings of $0.55 per share on revenue of $23.47M. iRadimed beat the earnings estimate in 5 of its last 8 reports, moving 8.6% on average across the report.
What is iRadimed’s 52-week high and low?
iRadimed’s 52-week high is $107.90 and its 52-week low is $71.34; it closed at $89.47 on Oct 12, 2026, +18.6% over the past year.
Is iRadimed stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (seasonality), 2 as mixed (trend and gekkoindex) and 2 as headwinds (fair value and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See iRadimed the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.